Ruxolitinib - Incyte Corporation

Drug Profile

Ruxolitinib - Incyte Corporation

Alternative Names: INC-424; INCB 018424 phosphate; INCB-018424; INCB-18424; Jakafi; Jakavi; ruxolitinib phosphate

Latest Information Update: 17 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Incyte Corporation
  • Developer Dana-Farber Cancer Institute; H. Lee Moffitt Cancer Center and Research Institute; Incyte Corporation; Lymphoma Academic Research Organisation; Novartis; RWTH Aachen University; Sunnybrook Health Sciences Centre; Tufts-New England Medical Center; University Health Network of Toronto; University of Cologne; University of Texas M. D. Anderson Cancer Center
  • Class 2 ring heterocyclic compounds; Antineoplastics; Antipsoriatics; Antirheumatics; Cyclopentanes; Nitriles; Pyrazoles; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Polycythaemia vera; Myelofibrosis; Essential thrombocythaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Myelofibrosis; Polycythaemia vera
  • Phase III Essential thrombocythaemia; Graft-versus-host disease
  • Phase II Alopecia areata; Atopic dermatitis; Breast cancer; Chronic lymphocytic leukaemia; Chronic myelomonocytic leukaemia; Haematological malignancies; Hodgkin's disease; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma; Thalassaemia; Vitiligo
  • Phase I/II Acute myeloid leukaemia; Chronic myeloid leukaemia
  • No development reported Psoriasis
  • Discontinued Colorectal cancer; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Rheumatoid arthritis

Most Recent Events

  • 09 Apr 2018 Novartis Pharmaceuticals plans a phase I/II trial for Graft Versus Host Disease in June 2018 , (NCT03491215)
  • 15 Feb 2018 Incyte Corporation has issued and pending patents for ruxolitinib in USA, European Union and Japan
  • 15 Feb 2018 Incyte Corporation completes enrolment in the phase III REACH-1 trial in Graft-versus host disease in USA (NCT02953678)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top